Alliance Pharmaceuticals (APH) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Alliance Pharmaceuticals has undergone a definitive transformation, completing the sale of its pharmaceutical division in January 2026 to become a focused, international consumer healthcare company. Its mission is to empower people to make a positive difference to their health by commercializing a portfolio of trusted brands like Kelo-Cote™ and Nizoral™. The company's growth strategy is three-pronged: driving organic growth through brand investment and geographic expansion, pursuing related innovation, and selectively acquiring complementary brands, all executed via an asset-light operational model.

Helping Damaged SkinSupporting Healthy Ageing

Technology Platform

A commercial and operational platform for consumer healthcare brand management, specializing in brand acquisition, lifecycle management, regulatory compliance, and global multi-channel commercialization via an asset-light, outsourced manufacturing model.

Opportunities

Significant opportunity lies in expanding core brands like Kelo-Cote™ into new geographic markets and e-commerce channels, particularly in high-growth APAC regions.

The company's pure-play focus and strong balance sheet post-divestiture also position it to capture consolidation opportunities in the fragmented consumer health sector through accretive acquisitions.

Risk Factors

Key risks include over-reliance on key brands and acquisition-driven growth, potential supply chain disruptions from the fully outsourced manufacturing model, and intense competition from larger global OTC players and private labels in core markets.

Competitive Landscape

Alliance competes with global OTC giants (e.g., Reckitt, Bayer) and specialist consumer health firms. Its differentiation is based on agility, focused brand attention, and a 'glocal' commercial execution model, allowing it to acquire and scale niche brands more effectively than larger, less-focused competitors.

More companies in Small Molecule Drugs →More companies in United Kingdom →